UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data shown on the profile page to:

http://www.ucl.ac.uk/finance/secure/research/post_award
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
 More search options
Dr Vincenzo Libri
Head of The Leonard Wolfson Experimental Neurology Centre
UCL, Institute of Neurology & The National Hospital for Neurology and Neurosurgery
23 Queen Square
London
WC1N 3BG
Appointment
  • Head of the Leonard Wolfson Experimental Neurology Centre
  • IoN Administration
  • Institute of Neurology
  • Faculty of Brain Sciences
Biography

Dr Libri is a consultant Clinical Pharmacologist and Head of the Leonard Wolfson Experimental Neurology Centre (LWENC) at the UCL, Institute of Neurology and UCLH, National Hospital for Neurology and Neurodegeneration. The LWENC was established as part of a £20million capital award from the Wolfson Foundation and was specifically designed to undertake experimental medicine studies and early phase clinical trials (including first-in-man) aimed at identifying potential disease modifying therapies in the field of Neurology and Neurodegeration, including Alzheimer's disease, Parkinson disease, Huntington's disease, Multiple Sclerosis, Stroke, Prion disease and movement disorders. In his capacity as Head of the LWENC, Dr Libri provides leadership to a multidisciplinary research team made up of medical, nursing and operational staff, and chairs the Protocol Review Board of the LWENC Clinical Facility, prioritising studies in line with the overall strategy of the Wolfson research program and conducting risk assessments and safety monitoring for all studies adopted by the Centre.

From 1990 to 1998, Dr Libri was an Academic Clinical Fellow and Welcome Trust and MRC grant holder at the School of Pharmacy, University of London. In 1994 he was appointed as Lecturer in Clinical Pharmacology within the University of Rome, Italy. From 1998 to 2008 he worked in multiple Pharmaceutical Companies (GlaxoWellcome, Eli Lilly and GlaxoSmithKline), undertaking direct responsibility and leadership for translational medicine and early phase clinical trials in healthy volunteers and patients across a broad range of neuro-psychiatric diseases, with a focus on pain and Alzheimer's disease. In 2004 he was appointed as Head of Exploratory Medical Sciences within the Neurology Centre of Excellence in Drug Discovery at GlaxoSmithKline. From 2009 to 2013 he was the Head of Clinical Studies at the NIHR, Wellcome Trust Imperial Clinical Research Facility at Imperial College London where he managed the portfolio of clinical studies and oversaw the running of the research facility, ensuring high standards of medical governance, GCP compliance and appropriate medical monitoring of volunteers participating in clinical studies. He also undertook Principal Investigator responsibilities for Phase I-II clinical trials and experimental medicine studies in healthy volunteers and patients across a variety of the therapeutic areas.

Research Themes
Research Summary

Dr Libri has long lasting expertise in clinical pharmacology, experimental neurology, translational medicine and early phase drug development from first time in man through through to proof of concept. He has mixed academic-industry experience and his main research interests include Alzheimer's disease, Friedreich's ataxia, aging and neuropathic pain. He has published several peer reviewed original research papers in international medical journals including the Lancet. Particularly notable are a series of clinical trials exploring for the first time the therapeutic benefit of established and putative new drugs in health volunteers and patients, namely: effects of high doses of the histone deacetylase inhibitor nicotinamine  in up-regulating frataxin levels in Friedriech's ataxia patients (this study represented one of the first epigenetic therapeutic attempts for a disease other than cancer); efficacy of capsaicin 8% patches for the reduction of treprostinil-induced pain in pulmonary hypertension patients; safety, pharmacokinetic and pharmacodinamic effects of a novel sirtuin-1 activator in elderly volunteers; characterisation of the TSPO binding status and steroid production in healthy volunteers; characterisation of amyloid imaging tracers (11C-PIB, FDDNP) in Alzheimer's disease pathologies.

Teaching Summary

Dr Libri is currently the Director of the Master in Translational Neurology within the Faculty of Brain Sciences at UCL (https://www.ucl.ac.uk/ion/education/courses/mresintranslationalneurology). He has several years of teaching experience ranging from undergraduate to postgraduate medical students, both within Italian Universities  (where he holds an honorary appointment as Professor in Clinical Pharmacology) and in the UK. At Imperial College London, he coordinated the MRes in Translational Medicine for BSc and MBBS graduates and provided practical classes and lectures on clinical pharmacology and pharmacokinetics, translational medicine and experimental medicine, clinical trial design and safety endpoints, surrogate markers and emerging technologies applied to drug development. He was an invited lecturer at the University of Oxford to give lectures to PhD students undergoing interdisciplinary drug discovery and biomedicine courses.


Academic Background
2014 FRCP Fellow of the Royal College of Physicians Royal College of Physicians
1988 CCST Certificate of Completion of Specialist Training Universita degli Studi di Napoli - Federico II
1985 MD Doctor of Medicine Universita degli Studi di Napoli - Federico II
Please report any queries concerning the data shown on this page to:

https://www.ucl.ac.uk/hr/helpdesk/helpdesk_web_form.php
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by